US 12,274,791 B2
Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement
James R. Komorowski, Trumbull, CT (US)
Assigned to Bonafide Health, LLC
Filed by Bonafide Health, LLC, Harrison, NY (US)
Filed on Sep. 25, 2023, as Appl. No. 18/372,560.
Application 17/558,763 is a division of application No. 16/524,591, filed on Jul. 29, 2019, granted, now 11,241,388, issued on Feb. 8, 2022.
Application 16/524,591 is a division of application No. 15/215,979, filed on Jul. 21, 2016, granted, now 10,363,222, issued on Jul. 30, 2019.
Application 18/372,560 is a continuation of application No. 17/686,827, filed on Mar. 4, 2022, granted, now 11,801,224.
Application 17/686,827 is a continuation of application No. 17/558,763, filed on Dec. 22, 2021, granted, now 11,850,308.
Application 15/215,979 is a continuation of application No. 14/642,243, filed on Mar. 9, 2015, granted, now 9,421,170, issued on Aug. 23, 2016.
Application 14/642,243 is a continuation of application No. 13/857,813, filed on Apr. 5, 2013, granted, now 9,005,637, issued on Apr. 14, 2015.
Application 13/857,813 is a continuation of application No. 12/645,124, filed on Dec. 22, 2009, granted, now 8,586,061, issued on Nov. 19, 2013.
Application 12/645,124 is a continuation of application No. PCT/US2008/067736, filed on Jun. 20, 2008.
Claims priority of provisional application 60/946,357, filed on Jun. 26, 2007.
Prior Publication US 2024/0016746 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/24 (2006.01); A23L 33/15 (2016.01); A61K 9/00 (2006.01); A61K 31/155 (2006.01); A61K 33/24 (2019.01); A61K 45/06 (2006.01)
CPC A61K 9/209 (2013.01) [A23L 33/15 (2016.08); A61K 9/00 (2013.01); A61K 9/0053 (2013.01); A61K 31/155 (2013.01); A61K 33/24 (2013.01); A61K 45/06 (2013.01); A23V 2002/00 (2013.01); Y02A 50/30 (2018.01)] 6 Claims
OG exemplary drawing
 
1. A dosage form for oral administration comprising:
a therapeutic agent layer;
a nutritional supplement layer; and
a middle barrier layer disposed between the therapeutic agent layer and the nutritional supplement layer,
wherein the therapeutic agent layer and the nutritional supplement layer are positioned on opposing sides of the middle barrier layer; and
wherein the therapeutic agent is selected from the group consisting of anti-inflammatories, macromolecules, antifungals, antidepressants, antipsychotics, anesthetics, anxiolytics, anticonvulsants, nervous system stimulants, antiemetics, bronchodilators, decongestants, antibiotics, anti-virals, immuno-suppressants, hormonal contraceptives, selective estrogen receptor modulators, fertility agents, hallucinogens, mood stabilizers, angiotensin converting enzyme inhibitors, antiarrhythmics, antianginals, anticoagulants, antiplatelets, beta blockers, diuretics, thrombolytics, antidiarrheals, laxatives, antirheumatics, corticosteroids, muscle relaxants, anti-histamines, anti-diabetics, alpha glucosidase inhibitors, DPP-4 inhibitors, antihypertensives, vasodilators, protease inhibitors, vaccines, anti-protozoals, antihelmintics and any combination thereof.